Subscribe
Core coveragePRAX

Company profile / PRAX

Praxis Precision Medicines

Clinaptis stanceCautious
ConvictionMedium
Ticker
PRAX
Exchange
NASDAQ
Coverage
Catalyst profile
Updated
Aug 19, 2026
Essential Tremor / Developmental Epileptic Encephalopathies

Late-stage neuroscience company approaching three closely spaced catalysts across two franchises: broad-DEE EMERALD data, relutrigine’s SCN2A/SCN8A PDUFA, and ulixacaltamide’s essential-tremor PDUFA.

01 / Clinaptis view

The current read

Relutrigine’s narrow SCN2A/SCN8A franchise looks substantially de-risked after EMBOLD’s 53% placebo-adjusted seizure reduction. The more consequential question is whether that efficacy transports into the much larger, biologically heterogeneous DEE population being tested in EMERALD.

  1. Our simulations suggest EMERALD does not need another 53% result. Roughly 22.5% placebo-adjusted efficacy across the trial produces robust statistical power under our calibrated assumptions. The challenge is breadth rather than depth: enough partial sodium-channel sensitivity must extend beyond the genetically narrow population already demonstrated.
  2. Ulixacaltamide remains the largest component of our valuation, but EMERALD is the catalyst with the greatest potential to establish a third meaningful value pillar.
02 / Consensus gap

Where the market may differ

The market may frame EMERALD as a binary test of whether EMBOLD’s 53% seizure reduction replicates in broader DEE. We think that sets the clinical bar too high while potentially setting the investment bar too low.

  1. A substantially smaller aggregate effect can produce a statistically robust trial. But statistical significance alone is insufficient: subtype consistency, responder breadth, placebo behavior and safety in loss-of-function sodium-channel disease determine whether a positive result supports a broad franchise or merely identifies another narrow responsive subgroup.
  2. On our attribution, broad DEE is already valued close to our unconditional estimate. The important upside case is therefore not simply a positive primary endpoint, but evidence that relutrigine’s efficacy is broad enough to support a commercially useful DEE label.
Coverage state
Catalyst profile
What the review turns on
Key variable

Breadth, not another 53%.

Next catalyst

Relutrigine · EMERALD topline in broad DEE · 4Q26

03 / Pipeline

Key programs

4 assets · 5 programs

AssetIndicationStageNext event
Relutrigine
Broad developmental and epileptic encephalopathies
Phase 3
EMERALD topline · 4Q26Broad DEE across more than 50 etiologies; approximately 200 patients
SCN2A / SCN8A developmental and epileptic encephalopathies
NDA Review
Relutrigine PDUFA · Dec 27, 2026Potential approval in narrow SCN2A/SCN8A epilepsy
Ulixacaltamide
Essential tremor
NDA Review
Ulixacaltamide PDUFA · Jan 29, 2027Potential foundation of the essential-tremor franchise
Vormatrigine
Epilepsy
Registrational
Program updates
Elsunersen
SCN2A-DEE
Registrational
Program updates
04 / Connected research

Published on PRAX

View full archive
  1. 01

    Praxis (PRAX): EMERALD Doesn't Need Another 53% Seizure Reduction

    EMERALD needs roughly 22.5% placebo-adjusted efficacy across broad DEE, not another EMBOLD-like 53%; who responds and how the primary analysis measures the mixture determine the franchise value.

    Read
  2. 02

    Praxis: Odds Favor Ulixacaltamide Approval in ET, but…

    The regulatory case looks settled. The commercial case does not: patients × price × persistence now decide whether today's valuation holds.

    Read